Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B1655
- Development stage
- Phase 1
- Lead developer
- Tasly Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
B1655 is a recombinant humanized monoclonal antibody developed by Tianjin Tasly Biopharmaceutical for the treatment of hypercholesterolemia. It functions as a PCSK9 inhibitor, binding to proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. This action increases the density of LDLRs, facilitating the clearance of circulating low-density lipoprotein cholesterol (LDL-C). B1655 is currently being evaluated in Phase 3 clinical trials for patients with primary hypercholesterolemia and mixed dyslipidemia.
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on B1655.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B1655.